There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on IO Biotech (IOBT – Research Report) and Iterum Therapeutics (ITRM – Research Report) with bullish sentiments.
IO Biotech (IOBT)
In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on IO Biotech. The company’s shares closed last Tuesday at $1.42.
According to TipRanks.com, Werber is a 5-star analyst with an average return of
IO Biotech has an analyst consensus of Strong Buy, with a price target consensus of $9.00.
See the top stocks recommended by analysts >>
Iterum Therapeutics (ITRM)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Iterum Therapeutics, with a price target of $7.00. The company’s shares closed last Tuesday at $1.53.
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Iterum Therapeutics with a $6.50 average price target, representing a 342.2% upside. In a report issued on April 30, H.C. Wainwright also maintained a Buy rating on the stock with a $6.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IOBT:
- IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
- IOBT Upcoming Earnings Report: What to Expect?
- IO Biotech Board Member Jack Nielsen Resigns Due to Health
- IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- IO Biotech participates in a conference call with Jefferies
